Reduction in serum clusterin is a potential therapeutic biomarker in patients with castration-resistant prostate cancer treated with custirsen

Cancer Medicine

Volumn 2, Issue 4, 2013, Pages 468-477

  Blumenstein, Brent ^a   Saad, Fred ^b   Hotte, Sebastien ^c   Chi, Kim N ^d   Eigl, Bernhard ^e   Gleave, Martin ^e   Jacobs, Cindy ^f  

^a Trial Architecture Consulting   (United States)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c JURAVINSKI CANCER CENTRE   (Canada)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

^e VANCOUVER PROSTATE CENTRE   (Canada)

^f Oncogenex Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CHEMOTHERAPY; CLUSTERIN; CUSTIRSEN; MCRPC;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLUSTERIN; HUMANS; MALE; OLIGONUCLEOTIDES, ANTISENSE; ORCHIECTOMY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; THIONUCLEOTIDES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84896317219     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.93     Document Type: Article

References (40)